ome time ago, our laboratory proposed the existence of three B lymphocyte lineages (B-1a, B-1b, and B-2) in the mouse (1-3). We based this proposal on in vivo reconstitution studies demonstrating that progenitors for these lineages are enriched differentially in traditional sites for lymphocyte progenitors, i.e., B-1a progenitors are found principally in fetal liver, neonatal spleen, and neonatal bone marrow (BM), whereas B-1b and B-2 progenitors are found principally in adult BM. In the ensuing years, alternate theories were advanced suggesting that antigendriven differentiation of mature B cells accounted for the development of these functionally distinct B cells subsets (4-9). However, in a recent paper, directly demonstrate that B-1a, B-1b, and B-2 belong to three separate lineages by showing that they derive from phenotypically and temporally distinct progenitors, i.e., progenitors for B-2 cells are phenotypically distinct from progenitors for B-1a and B-1b; among progenitors for B-1 cells, B-1a progenitors are found principally in neonates, whereas progenitors for B-1b are found principally in adults.
S
ome time ago, our laboratory proposed the existence of three B lymphocyte lineages (B-1a, B-1b, and B-2) in the mouse (1) (2) (3) . We based this proposal on in vivo reconstitution studies demonstrating that progenitors for these lineages are enriched differentially in traditional sites for lymphocyte progenitors, i.e., B-1a progenitors are found principally in fetal liver, neonatal spleen, and neonatal bone marrow (BM), whereas B-1b and B-2 progenitors are found principally in adult BM. In the ensuing years, alternate theories were advanced suggesting that antigendriven differentiation of mature B cells accounted for the development of these functionally distinct B cells subsets (4) (5) (6) (7) (8) (9) . However, in a recent paper, Montecino-Rodriguez et al. (10) directly demonstrate that B-1a, B-1b, and B-2 belong to three separate lineages by showing that they derive from phenotypically and temporally distinct progenitors, i.e., progenitors for B-2 cells are phenotypically distinct from progenitors for B-1a and B-1b; among progenitors for B-1 cells, B-1a progenitors are found principally in neonates, whereas progenitors for B-1b are found principally in adults.
Studies here provide key support for the existence of the distinct B cell lineages by showing that the predominant B cell development pathway in adults, where B-2 development predominates, is phenotypically distinct from the predominant pathway in neonates, where B-1 development predominates. In essence, we show that syndecan-1 (CD138) and MHC class II (I-A) are both expressed throughout B cell development in the predominant B cell pathway adult BM, beginning when Ig rearrangement is initiated [at Hardy fraction (Fr.) B (11) ] and persisting thereafter (I-A), or terminating when the B cells reach maturity (CD138). In contrast, neither marker is expressed during early B cell development in the predominant pathway in neonatal BM and spleen, where I-A appears initially on mature B cells (12, 13) , and CD138 is not detectable on most of the developing B cells.
Results

CD138 Expression Distinguishes the Predominant Neonatal B Cell
Development Pathway from the Predominant Pathway in Adults. To identify the standard subsets in the B cell development pathway, i.e., Fr. A-F (11), we analyzed the stained adult or neonatal BM cells according to the scheme shown in Fig. 1 Fig. 2A Upper show that CD138 (a surface proteoglycan that binds to the extracellular matrix and is expressed on plasma cells and pre-B cells) (14) is not expressed or is expressed at low levels in the predominant B cell development subsets (Fr. A-F) in neonates ( Fig. 2A Upper, shaded histograms) . In contrast, the predominant B cell development subsets in adults express relatively high levels of CD138, from Fr. B onward. In Fr. F, which contains a mixture of newly developed B cells and recirculating B cells, approximately half of the cells still express CD138, and some of the others appear to have down-regulated CD138 to different extents ( Fig. 2A Upper, unshaded histograms). Consistent with the loss of CD138 on mature B cells, none of the B cells in spleen express CD138 (data for splenic IgM ϩ IgD ϩ are shown in Fig. 2A Lower) . Overall, we detect four levels of CD138 expression. Plasma cells, which have been gated out from the data shown here, express the highest CD138 levels, i.e., Ϸ10-fold above the CD138 levels expressed on CD138-expressing cells during B cell development. Gating on the Fr. A-C (a combined subset in which most of the cells are from Fr. B) shows three levels of CD138 expression (CD138 hi , CD138 int , and CD138 Ϫ ) and varying frequencies of cells at these expression levels depending on the source of the cells (Fig. 2B) . In adult BM, the frequency of CD138 hi is the highest, and the frequency of CD138 int is greater than CD138
Ϫ . In neonates, the reverse is true: The majority of cells are CD138 Ϫ cells, although some CD138 int and a few CD138 hi cells are detectable. These striking differences in CD138 expression, which are fixed early in the B cell development, suggests that the three levels of CD138 expression may distinguish the progenitors for B-1a, B-1b, and B2 cells. Data presented in the next section support this hypothesis. Ϫ cells that express intermediate levels of the ''CD45R'' (B220-6B2) determinant detected by the B220͞RA3-6B2 monoclonal antibody (circular gates, Fig. 3 ). This subset, which is basically Fr. A with AA4.1 Ϫ cells excluded and a proportion of CD19 low Fr. B included, is mainly present in adult BM.
In contrast, the B-1a progenitors, which are found mainly in neonatal BM, and the B-1b progenitors, which are found mainly in adult BM, are located in an AA4.1 ϩ CD19 ϩ subset similar to Fr. B with respect to expression of these markers but containing cells that only express minimal levels of the B220-6B2 determinant (designated as B220-6B2 lo/neg ). These cells, MontecinoRodriguez and colleagues (10) show, express other B220 isoforms and hence are committed to the B lineage. Consistent with this commitment, and with the similarity of these subsets to Fr. B, we find that the cells in both subsets express CD24 at levels typical for Fr. B.
With hindsight, the low expression of B220-6B2 on B-1 progenitors is not surprising. Although this determinant is readily detectable on mature B-1 cells, it is usually expressed at lower levels on these cells than on B-2 cells (18, 19) . In fact, the B220-6B2 monoclonal antibody was adopted for general use for B cell identification in our laboratory (and elsewhere) specifically because, although its expression overlaps on B-1 and B-2 cells, it provides an opportunity to estimate whether B-1 or B-2 cells predominate in a given B cell population (18) .
Results from our studies with the progenitor subsets defined by Montecino-Rodriguez and colleagues (10) strongly support the idea that CD138 expression distinguishes early-stage B lineage progenitors. Data in Fig. 3 show that CD138
hi cells are enriched in the B-2 progenitor subset. CD138
Ϫ cells, in contrast, constitute Ϸ90% of the neonatal subset that gives rise to B-1a cells; CD138 int constitute Ϸ50% of the adult subset that predominantly gives rise to B-1b cells.
Analysis of this latter subset (AA4.1 ϩ , CD19 ϩ , and B220-6B2 Ϫ/lo BM from adult BM) is complicated by the presence of substantial numbers of cells at all three CD138 levels (Fig. 3) . Although approximately half the cells express CD138
int , a quarter is CD138 hi , and the remainder is CD138 Ϫ . The CD138 Ϫ cells in this subset likely reflect the presence of progenitors for B-1a cells, which this adult subset also reconstitutes (although to a lesser extent that B-1b). The CD138 hi cells, in contrast, likely represent contamination from the previously defined AA4.1 ϩ , CD19 ϩ Fr. B, which expresses intermediate levels of B220-6B2 but does not otherwise differ from the B220-6B2 Ϫ/lo subset defined by Montecino-Rodriguez.
Collectively, the data cited above provide good reason to believe that the expression of CD138 on developing B cells (Fr. B-E) will prove to distinguish reliably between the progenitors for each of the B cell lineages. However, in the absence of data from sorting and transfer studies with this marker, these findings must still be considered provisional. To evaluate whether CD138 is transiently expressed during B-1 development, we sorted and cultured the predominant pre-B cell subsets in adult and neonatal BM, i.e., CD138
hi from adults and CD138
Ϫ from neonates and determined how͞whether CD138 expression changes as these two types of pre-B cells mature (Fig. 4) hi , despite the initiation of surface Ig production (Fig. 4) .
Preliminary studies with sorted pre-B cells cultured for 90 h indicates that Ϸ80% of the CD138 ϩ pre-B cells sorted from adult BM express IgM and that the majority of these cells down- regulate CD138 expression and up-regulate IgD (data not shown). The expression of IgD, however, does not appear to coordinate with the down-regulation of CD138 (data not shown).
Discussion
We show here that CD138 and I-A expression distinguishes the predominant B cell development pathway in adult mice from the predominant pathway in neonates. The expression of CD138 begins early in B cell development (at Fr. B) and continues until B cells mature and leave the marrow; however, the frequency of CD138 ϩ cells among developing B cells differs strikingly between adults and neonates. In adult BM, most (Ͼ70%) of the developing B cells express CD138; in neonatal BM and spleen, CD138 is only expressed on a minority (Ͻ10%) of these cells. The I-A expression pattern is qualitatively similar to the CD138 pattern, except that I-A expression begins somewhat later during development and persists when the mature B cells leave the BM.
Quantitative differences in CD138 expression further distinguish the early B cell progenitors (Fr. A and B) in animals of different ages. Using the staining and gating criteria that Montecino-Rodriguez et al. (10) used to sort progenitors for the B-1a, B-1b, and B-2 subsets from adult and neonatal BM, we show here that CD138 Ϫ , CD138 int , and CD138 hi cells predominate, respectively, in the subsets in which B-1a, B-1b, and B-2 progenitors were shown to predominate (Fig. 2) . These findings support and extend evidence from the demonstrations by the MontecinoRodriguez and Hardy groups (refs. 10 and 15, respectively), based on the sorting and transferring of cells early in B cell development pathway, that independent B cell progenitors give rise to B-1a, B-1b, and B-2 cells. Thus, collectively, there is strong support for the conclusion that these phenotypically and functionally distinct B cells belong to distinct developmental lineages (see Fig. 5 ).
We had proposed the existence of the three B cell lineages some time ago (1, 2, 21), based on evidence from reconstitution studies in which B220 Ϫ progenitors were sorted from adult BM at a stage before initiation of rearrangement and were cotransferred with B cell progenitors from fetal liver into lethally irradiated recipients. Six weeks (or more) after transfer, B-2 cells were reconstituted equivalently from both fetal and adult progenitors. B-1a cells, however, were reconstituted almost exclusively from the fetal progenitors, indicating that these progenitors are well represented in neonates but are rare in adult BM. B-1b cells were well reconstituted from fetal sources but could also be recovered in reasonable numbers from adult progenitors, indicating that the progenitors for B-1a and B-1b were distinct and suggesting that B-1b progenitors are likely to also be distinct from the progenitors for B-2 cells.
Hardy and Hayakawa (15) between the two types of progenitors, the inherent differences in the progenitors and their progeny means that they still should still be assigned to distinct lineages.
Nevertheless, without the direct demonstration that the two types of progenitors coexist at the same site and can be physically isolated from one another, the findings from these early studies left room for alternate hypotheses (4-9). Thus, until the Montecino-Rodriguez group published their findings demonstrating the isolation of phenotypically distinct progenitors for B-1 and B-2 cells from adult BM, the B lineage issue had not been definitively settled (22) .
The alternate hypotheses proposed over the years place B-1a, B-1b, and B-2 within the same lineage, arguing that these phenotypically distinct B cells all derived from the same progenitor but are triggered late in differentiation, after IgH rearrangement is complete, to assume one of the B cell (lineage) phenotypes in response to stimulation and selection with distinctive antigens. Our findings here, coupled with the findings from Montecino-Rodriguez and colleagues (10) demonstrate otherwise. In essence, we show that the B cell development pathways diverge phenotypically at least as early as Fr. B and thus clearly before the V to DJ rearrangement. In addition, Montecino-Rodriguez and colleagues show definitively, by sorting and transferring phenotypically distinct subsets of early B cell progenitors from BM, that this lineage commitment occurs at a stage well before IgH rearrangement and expression that could be used for antigen-dependent selection. Thus, the idea that antigen recognition determines whether developing B cells become B-1a, B-1b, or B-2 cells now has been shown to be incorrect.
Locating B-1a, B-1b, and B-2 cells in separate developmental lineages does not, of course, rule out key roles for antigen in negative or positive selection, or in determining the persistence of B cells expressing particular receptors. Instead, the recognition that the developmental pathways for these lineages differ provides a context for thinking about how͞whether different antigen-dependent mechanisms operate to determine the lineage repertoires.
Hardy, for example, has proposed that the VDJ rearrangements that form good VpreB͞5 pre-BCR complexes and positively select B-2 cells are actually toxic to developing B-1 cells, which can only pass this developmental checkpoint if VpreB͞5 pre-BCR complex formation fails (23) . This inherent mechanism would explain evidence presented earlier by Hardy's group (15) , which showed clearly that the committed B-1 progenitors in fetal liver maintained their developmental commitment to the unique B-1 repertoire, even in adult adoptive recipients (15) .
In addition, the mechanism Hardy (23) The presence of distinctive antibody repertoires in three lineages is, of course, fully compatible with their developmental distinctions. In fact, it is likely that this functional distinction underlies what we have suggested is the sequential evolution of the lineage in response to progressively more sophisticated immune challenges (1, 21, 26, 27) . Thus, although B-1a and B-1b cells tend to produce autoreactive and innate antibody responses, the putatively more highly evolved B-2 cells produce antibodies to a wider variety of antigens and, when stimulated, differentiate to long-lived memory B cells capable of rapidly responding with high affinity responses to secondary antigenic challenges.
Further studies are required to characterize the B lineage progenitors discussed here and to identify the stem cell(s) and intermediate progenitors from which these progenitors derive. Now, with the definitive demonstration that the B lineage compartment is subdivided into (at least) three lineages, studies aimed at understanding the developmental origins and functional properties that distinguish these lineages can begin in earnest.
Materials and Methods
Mice and Tissue Preparation. BALB͞cN and C.B-17 mice were bred and maintained at the Department of Comparative Medicine at Stanford University. BM cells were extruded from femurs of adult or 3-to 4-day-old neonatal mice by using staining medium (RPMI medium 1640 ϩ 3% newborn calf serum)-filled syringes, then washed, filtered through nylon mesh, and resuspended at 25 ϫ 10 6 cells per ml. Single-cell suspensions of spleens were prepared by first grinding the spleens with frosted slides and then by gentle passage through nylon mesh. The red blood cells were lysed by incubation with chilled 0.14 M NH 4 Cl and 20 mM Tris (pH 7.4) for 2 min. These splenic cells were then washed with staining medium and resuspended at 25 ϫ 10 6 cells per ml.
FACS Analysis and Sorting. Cell suspensions from BALB͞cN or C.B-17 adult and neonate BM or spleen were prestained with anti-CD16͞CD32 mAb to block Fc␥RII͞III receptors and stained on ice for 15 min with the following fluorochromeconjugated antibodies in a ten-color staining combination: FITC-CD19 (1D3) or FITC-I-A d (AMS-132.1); PE-CD43 (S7); biotin-CD138 (281-2); PECy5.5-CD24 (30F1); PECy7-IgD (11-26); Alexa594-BP-1 (6C3); APC-B220 (RA3-6B2), referred to here as B220-6B2; APCCy5.5-AA4.1; APCCy7-IgM (331); and, as a ''dump reagent'' with which to gate out unwanted cells, a mixture of cascade blue-conjugated CD4 (GK1.5), CD8a (53-6.7), Gr-1 (8C5), and F4͞80. After being stained with this stain set, the cells were washed with staining medium and stained again on ice for 15 min with streptavidin-CyChrome (BD Pharmingen), a second-step reagent that reveals biotin-coupled antibodies. The fluorochrome-conjugated antibodies were either purchased from BD Pharmingen or custom conjugated in the Herzenberg laboratory (Stanford, CA).
After washing away excess reagents, the stained cells were resuspended in staining medium containing 10 g͞ml propidium iodide. Cells that stained with propidium iodide (dead cells) were excluded from analysis and sorting in all cases. Cells were analyzed and sorted on the Stanford shared FACS facility Hi-Dimensional FACS (Hi-D FACS) instruments, either on the FACSAria with DiVa electronics (Becton Dickinson) or on a hybrid instrument (''Flasher II'') in which a FACS II bench is coupled to FACS DiVa electronics. Staining protocols were designed with FACSXPERT (http:͞͞sciencexperts.com), and data were analyzed with FLOWJO software (http:͞͞treestar.com).
Cell Culture. Between 5 ϫ 10 4 and 8 ϫ 10 4 sorted pre-B cells from adult or neonatal BM were cultured in 96-well plates in 300 l of deficient Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS, 10 Ϫ5 M 2-mercaptoethanol, 2 mM glutamine, and 100 g͞ml penicillin and streptomycin. Cells were cultured for 36 or 96 h at 37°C in 7% CO 2 ambient oxygen incubators before FACS analysis. No stromal lines were used, and no cytokines were added.
